← Leaderboards
Valerie Israel
University Of Southern California
$885,479
Attributed
$885,479
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$885,479 · 3
By mechanism
M01$885,479 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Jeffrey Y Wong$938,530
- Wei-Chiang Shen$4,041,009
- Ite A Laird-Offringa$7,799,915
- Kathleen R Ell$9,983,182
- Robert C Seeger$12,536,093
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchColony Stimulating FactorCombination Cancer TherapyPaclitaxelPharmacokineticsHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationFemaleFemale Reproductive System NeoplasmIntravenous AdministrationNeoplasm /Cancer Classification /StagingNeoplasm /Cancer ImmunotherapySmall Cell Lung CancerBreast NeoplasmsWomen'S HealthCamptothecinCarboplatinClearance RateClinical Trial Phase IDosageDoxorubicinDrug Administration Rate /Duration
Grant awards (15)
PHASE I STUDY OF PACLITAXEL (TAXOL) AS A SHORT IV INFUSION$0
M01 · FY2002 · RR
9 AMINOCAMPTOTHECIN PLUS G CSF IN SMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
TAXOL AND DOXIL IN PATIENTS WITH ADVANCED BREAST AND GYNECOLOGICAL MALIGNANCIES$0
M01 · FY2002 · RR
PHASE I STUDY OF PACLITAXEL (TAXOL) AS A SHORT IV INFUSION$155,764
M01 · FY2001 · RR
TAXOL AND DOXIL IN PATIENTS WITH ADVANCED BREAST AND GYNECOLOGICAL MALIGNANCIES$155,764
M01 · FY2001 · RR
9 AMINOCAMPTOTHECIN PLUS G CSF IN SMALL CELL LUNG CANCER$155,764
M01 · FY2001 · RR
PHASE I STUDY OF PACLITAXEL (TAXOL) AS A SHORT IV INFUSION$0
M01 · FY2001 · RR
9 AMINOCAMPTOTHECIN PLUS G CSF IN SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
TAXOL AND DOXIL IN PATIENTS WITH ADVANCED BREAST AND GYNECOLOGICAL MALIGNANCIES$0
M01 · FY2001 · RR
9 AMINOCAMPTOTHECIN PLUS G CSF IN SMALL CELL LUNG CANCER$155,764
M01 · FY2000 · RR
PHASE I STUDY OF PACLITAXEL (TAXOL) AS A SHORT IV INFUSION$155,764
M01 · FY2000 · RR
PHASE I STUDY OF PACLITAXEL (TAXOL) AS A SHORT IV INFUSION$35,553
M01 · FY2000 · RR
TAXOL AND DOXIL IN PATIENTS WITH ADVANCED BREAST AND GYNECOLOGICAL MALIGNANCIES$35,553
M01 · FY2000 · RR
9 AMINOCAMPTOTHECIN PLUS G CSF IN SMALL CELL LUNG CANCER$35,553
M01 · FY2000 · RR
TAXOL AND DOXIL IN PATIENTS WITH ADVANCED BREAST AND GYNECOLOGICAL MALIGNANCIES$0
M01 · FY2000 · RR